This page is part of the FHIR Specification v6.0.0-ballot1: Release 6 Ballot (1st Draft) (see Ballot Notes). The current version is 5.0.0. For a full list of available versions, see the Directory of published versions
Interaction effect example
{
"resourceType" : "ClinicalUseDefinition",
"id" : "example-interaction",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ClinicalUseDefinition</b><a name=\"example-interaction\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ClinicalUseDefinition "example-interaction" </p></div><p><b>StructureDefinition Work Group</b>: brr</p><p><b>type</b>: interaction</p><p><b>subject</b>: <a href=\"medicinalproductdefinition-example.html\">MedicinalProductDefinition/example</a></p><blockquote><p><b>interaction</b></p><blockquote><p><b>interactant</b></p><p><b>item</b>: alphaconazole <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (interactant#alphaconazole)</span></p></blockquote><blockquote><p><b>interactant</b></p><p><b>item</b>: betaconazole <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (interactant#betaconazole)</span></p></blockquote><p><b>type</b>: Inhibitor <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (interactionsType#Inhibitor)</span></p><h3>Effects</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td>Increased plasma concentration <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></td></tr></table><p><b>management</b>: Careful monitoring of dose <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p></blockquote></div>"
},
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "brr"
}],
"type" : "interaction",
"subject" : [{
"reference" : "MedicinalProductDefinition/example"
}],
"interaction" : {
"interactant" : [{
"itemCodeableConcept" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/interactant",
"code" : "alphaconazole"
}]
}
},
{
"itemCodeableConcept" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/interactant",
"code" : "betaconazole"
}]
}
}],
"type" : {
"coding" : [{
"system" : "http://ema.europa.eu/example/interactionsType",
"code" : "Inhibitor"
}]
},
"effect" : {
"concept" : {
"text" : "Increased plasma concentration"
}
},
"management" : [{
"text" : "Careful monitoring of dose"
}]
}
}
Usage note: every effort has been made to ensure that the
examples are correct and useful, but they are not a normative part
of the specification.